Feedback Share Discussion Threads

[lr2] 22/5/2015 14:28

Ten Bagger Thursday podcast.

Short intro to FDBK at 1 minute.

Main chat at 5:50.

[sja123] 18/5/2015 11:34

Looks like Stig talking to himself again....well, he is on my feed anyway :-)

[the stigologist] 18/5/2015 11:01

rampers sold or shocked into silence

[the stigologist] 18/5/2015 09:46

shockingly bad management for them to come out with a "we know no reason" RNS but then use the RNS Reach or NONRNS system to pump the stock prior to a placing

the chancers in charge of this promote and reduce or pump and dump should be being taken to task by shareholders but of course some of the largest shareholders are in on the con

[the stigologist] 18/5/2015 09:43

looks like some people can see what is coming here

placing probably at big discount

[the stigologist] 18/5/2015 00:03

this applies here

RNS reach ie NON rnses to ramp the stock to mug punters before they are hit with a placing ny crony capitalist management who treat private investors/mug punters with contempt

[norbert colon] 15/5/2015 13:33

Stig/21. The good thing about these BBs is the fact that they are an open forum for investors, traders and in fact anyone to comment on a particular share / company and generally it's great to get the mixed views of all involved. All I would add re: some of the comments in this board from yourselves is that:

1) the RNS re: share price movement has to be read in the context that any RNS that does not specify contract values and relate them to forecasts for the business are just business as usual. All the recent announcement are business as usual in some respect as they are a function of the company trading and undertaking business; they are not YET material with respect to orders etc and hence I understand why they released that statement although I agree that given their very small mcap and early start-up stature, the flurry of positive news does seem ironic / coincidental.

2) Let's not call others on this board liars or delve to similar levels. Go short if you think FDBK is all hot air.

Anyway, enjoy the weekend all and let's all hope for further news.

Nobby

[lr2] 15/5/2015 12:49

Suit yourself. I doubt you guys were ever interested in investing here anyway.

[21trader] 15/5/2015 12:47

lol

Another Rns.

How many can a company issue around a no reason for rise warning ?

[lr2] 15/5/2015 12:46

Money agreed up front. If TexRAD deemed not worthy of follow up after research concluded then money is refunded otherwise goes towards first year's usage.

[the stigologist] 15/5/2015 10:17

how is a research agreement (IE you spend money suporting the research but get no cash back) money in the bank ?

[blueball] 15/5/2015 10:05

AVO up 10%today another run back to 14p coming I prefer FDBK could perform well in the long term.

[lr2] 15/5/2015 09:57

Each of these 'rampey NON RNS' releases is money in the bank and with 80% profit margin. Long may the 'rampey NON RNS' releases continue.

[the stigologist] 15/5/2015 09:53

another rampey NON RNS

[lr2] 15/5/2015 09:49

Take the space out of the link if you want to see the original news item. It's an ADVFN thing - they won't allow competition links to be pasted here.

investors.co.uk/companies/news/80392/feedback-teams-up-with-university-of-texas-for-texrad-research-80392.html

Feedback (LON:FDBK), a medical imaging software firm, is teaming up with the University of Texas to examine the potential clinical application of the company’s TexRAD tumour-imaging technology.

Specifically, experts in the MD Anderson Cancer Centre in Houston will look at how TexRAD derives ‘textures’ from routine diagnostic images, i.e. CT scans, of patients with kidney and adrenal cancer.

The study will include around 400 patients, although the results will not be used to influence or guide the treatment regimes.

Instead, the findings will help to strengthen the evidence base of TexRAD as an up and coming tumour texture heterogeneity analysis software.

Prof. Haesun Choi, who will lead the study, said limitations of the size-based traditional evaluation of solid tumours have been well recognised.

“More reliable user-friendly biomarkers that can reflect the tumour response and that can be used in risk-stratification are needed.

“Analysing the tumour heterogeneity on CT images may provide insights of tumours that may be useful in evaluating the tumour response.”

Earlier this week, Feedback signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust.

Under the deal, experts will investigate the potential future clinical application of Feedback's TexRAD on CT image data of patients with kidney stones.

Feedback shares added 1% to 2.1p this morning.

[blueball] 15/5/2015 08:03

Another RNS.

[svenice7] 14/5/2015 17:59

Long term this will rocket

[kenwrong] 13/5/2015 07:49

FDA approval will be important for Feedback, but the recent bunch of contract wins and collaborations suggests to me this company will build a global reputation on the back of Texrad anyway. It is a microcap, the market cap is still just £4.1m and already partnering with giants like Siemens.

[blueball] 12/5/2015 10:04

Good summary sja FDA approval isn't the be all and end all.

[sja123] 12/5/2015 09:57

In fairness and for clarity, this is the latest on FDA approval from interims in February:

"TexRAD has been granted a European patent. The Group continues to make progress towards the launch later this year of a commercial version of its TexRAD software for the pharmaceutical trials market which is expected to be achieved following 21 CFR 11 self certification in the second quarter of 2015. We will continue to work with our distributor to gain momentum in this market.

The FDA approval application for the Group's software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015"

FDA approval is important, but not the be all and end all IMO...there is plenty of exposure outside of the FDA's remit, within Europe and the Far East...

Plus...the software is already being used now in US for evaluating drug trials in colorectal cancers by Imaging Endpoints as has been previously announced..that looks like an important step towards FDA approval IMO

All imo etc

[21trader] 12/5/2015 09:43

Exactly then you should not be suggesting anything.

"which is not far away"

[blueball] 12/5/2015 09:42

Am I an insider I don't think I am I know no more than you do.